Shots:
- argenx has reported P-III (ADAPT OCULUS) trial data on Vyvgart (efgartigimod alfa & hyaluronidase-qvfc; SC PFS) in adults with ocular MG, where Part A randomized pts to Vyvgart (QW × 4) or PBO PH20 SC with 4wk. follow-up, & Part B provided 2 cycles of 4 QW injections separated by a 4wk. interval
- Trial met its 1EP, showing significantly improved Myasthenia Impairment Index PRO ocular scores at Wk. 4 compared to PBO, with a 4.04 vs 1.99-point improvement in the overall population
- Trial also showed reduction in key ocular symptoms, incl. diplopia (double vision) & ptosis (drooping of the upper eyelids); data to be presented in a future conference, with results supporting planned sBLA submission to the FDA
Ref: argenx | Image: argenx | Press Release
Related News: argenx Receives Health Canada’s Approval for Vyvgart SC to Treat Chronic Inflammatory Demyelinating Polyneuropathy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
